Special Issue "Pharmacokinetics and Pharmacodynamics of Antibacterial and Antivirulence Drugs"
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 7226
In 2017, the WHO published a list of bacteria, including but not limited to the so-called ESKAPE pathogens, for which research of new antibiotics is of critical or high priority as a result of increasing antimicrobial resistance. Currently, less than 50 new antibacterial compounds have been investigated in clinical trials. This highlights that compounds with novel mechanisms of action are desperately needed. To enable translation from bench to bedside, novel compounds must first prove that they reach their target site, and that they are effective under in vitro and in vivo infection conditions. In addition to novel treatment options, more sophisticated treatment regimens of current antibacterial agents can help to lower the risk of rapid emergence of antimicrobial resistance. Therefore, the main goal of this Special Issue is to present contributions of novel approaches to fighting antimicrobial resistance as well as strategies to ameliorate current treatment regimens in human medicine. Some examples are as follows:
- Pharmacokinetic (PK) and pharmacodynamic (PD) studies of novel antibacterial or anti-virulence compounds.
- In vitro characterizations to understand PK/PD relations of novel or established antibacterial or anti-virulence compounds.
- In silico PK or PK/PD modeling approaches aiming at translation from early compounds towards the clinic.
- Animal PK or PK/PD studies of established antibacterial compounds with implications for current treatment regimens.
- PK studies of established antibacterial compounds in special patient populations.
- PK or PK/PD modeling approaches to study effects and/or enhance therapeutic effects in special patient populations.
Dr. Katharina Rox
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- clinical trials
- antimicrobial resistance
- antivirulence drugs
- antimicrobial use
- drug utilization studies
- PK/PD modeling